

KYOWA KIRIN

News Release

Kyowa Hakko Kirin California Announces Closure of Clinical Assay Division

La Jolla, CA, December 18, 2015 -- Kyowa Hakko Kirin California, Inc. (President: Yasunori Yamaguchi, Ph.D.; headquartered in La Jolla, California, "KKC"), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151; President and CEO: Nobuo Hanai, Ph.D., "KHK"), today announced the closure of its Clinical Assay Division as part of the company's plan to focus on early stage drug discovery.

The Clinical Assay Division was established in 2008 to support KHK's growing portfolio of North America based clinical studies on novel therapeutic products and to accelerate global clinical development activities of KHK.

"After considerable review, we made a strategic decision to close our Clinical Assay Division," said Yasunori Yamaguchi, Ph.D., President of KKC. "KKC will focus on early stage drug discovery research and external innovation activities."

Contact:

Kyowa Hakko Kirin California, Inc.

9420 Athena Circle

La Jolla, CA 92037

858-952-7000

contact@kyowa-kirin-ca.com

<http://kyowa-kirin.com/kkc>